Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05451602RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with RET changes
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
GuangzhouAges 18 years+ - NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT05367635RecruitingPhase 1
Testing a new drug for advanced stomach cancers with CLDN18.2
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05455918RecruitingPhase 2
Chemo with paclitaxel, ifosfamide, and cisplatin for high-risk germ cell tumors
This Phase 2 trial tests a specific chemotherapy combination (paclitaxel, ifosfamide, and cisplatin) for children and teens with newly diagnosed, high-risk germ cell tumors. It aims to improve outcomes by treating cancer cells with a stronger chemo plan.
SeoulAges 1–20 - NCT05522868RecruitingPhase 1
Tested drug for solid tumors after standard treatment stopped
This Phase 1 study tests SB17170 in people with solid tumors that have spread or grown despite standard treatments. It looks for safety and early signs of how well the drug might work when other options have failed.
SeoulAges 19 years+ - NCT05528341RecruitingPhase 1
CAR NK cell treatment trial for solid tumor cancers
This Phase 1 study tests a lab-made immune cell treatment (CAR-NK92 cells) for people with solid tumors that have not responded to earlier treatments. The goal is to see how safe it is and whether it can shrink tumors or help control cancer.
Xinxiang, HenanAges 18–75 - NCT05608148RecruitingPhase 1
GAIA-102 for relapsed or hard-to-treat childhood cancers
This Phase 1 study tests GAIA-102 in children and young adults whose cancer has returned or not responded to standard treatments. It aims to see if the treatment is safe and whether it may shrink tumors in certain pediatric solid cancers.
Fukuoka, FukuokaAges 1–24 - NCT05473624RecruitingPhase 1
Test drug HRS-1167 for advanced cancers that need new options
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
Beijing, Beijing MunicipalityAges 18 years+ - NCT05430373RecruitingPhase 1
Injection study for advanced solid tumors using tumor-fighting cells
This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.
Beijing, Beijing MunicipalityAges 18–70 - NCT05392699RecruitingPhase 1
Testing ABOD2011 for advanced solid tumors after standard treatment
This Phase 1 trial tests a new medicine (ABOD2011) in people with advanced solid tumors that have come back or spread after standard treatment. It may help by shrinking tumors and allows researchers to study the tumor by giving medicine directly into it and taking a biopsy.
BeijingAges 18 years+ - NCT05584800RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05580796RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A*02 positive solid tumors
This trial tests a personalized immune-cell treatment made from your own blood to target certain solid tumors. You may be eligible if your tumor has a specific protein pattern and you have tried standard treatments without success.
Beijing, Beijing MunicipalityAges 18–70 - NCT05417321RecruitingPhase 1/Phase 2
Test of HB0036 for advanced cancers that ran out of options
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Lafayette, IndianaAges 18 years+ - NCT05458219RecruitingPhase 1
Testing an antibody-drug treatment for solid tumors
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
Austin, TexasAges 18 years+ - NCT05367778RecruitingPhase 1/Phase 2
Study of HS-10370 for advanced cancers with KRAS G12C
This trial tests HS-10370, a new targeted medicine, in people with advanced solid tumors that cannot be treated with standard options. It focuses on cancers that have a specific change in the KRAS gene (KRAS G12C).
Wuhan, HubeiAges 18 years+ - NCT05170958RecruitingPhase 1/Phase 2
Study of LBL-024 for advanced cancers
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
Hefei, AnhuiAges 18–80 - NCT04824950Recruiting
Blood DNA test in newly diagnosed mediastinal large B-cell lymphoma
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
LyonAges 18 years+ - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT04712877Recruiting
Blood and tumor testing to choose the right lung cancer treatment
This trial tests tumor tissue and a blood sample to help doctors pick the most personalized treatment for people with suspected lung cancer. It may help ensure you get therapy matched to your specific tumor characteristics, especially when the cancer might be surgically removed.
Davis, CaliforniaAges Any age - NCT05013086RecruitingEarly Phase 1
Study of a targeted radioactive drug for αVβ3-positive tumors
This early-phase study tests whether a targeted radioactive medicine (177Lu-AB-3PRGD2) can shrink or control tumors that strongly match a specific target seen on special scans. It may help people whose current standard treatments are not working or are no longer working.
Beijing, Beijing MunicipalityAges 18–80 - NCT04891198RecruitingPhase 2
Envafolimumab for advanced cancers after other treatments
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
BeijingAges 18 years+ - NCT05038150RecruitingPhase 1/Phase 2
Early-stage drug study for advanced cancers that stopped responding
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
Gilbert, ArizonaAges 18–75 - NCT04866641RecruitingPhase 1
Early safety study of T-1201 for advanced solid tumors
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
Kaohsiung CityAges 20 years+ - NCT04945330Recruiting
Study for NTRK fusion cancers taking larotrectinib
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Multiple LocationsAges Any age
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.